-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shisiyao Group’s Guangxiang Pharmaceutical and Guolong Pharmaceutical Have Both Been Recognized as “Specialized, Refined, Distinctive, and Innovative” SMEs in Hebei Province.
Category:
发布时间：2021-09-03
【概要描述】
Recently, Hebei Guangxiang Pharmaceutical Co., Ltd. and Hebei Guolong Pharmaceutical Co., Ltd., subsidiaries of Shijiazhuang Sihua Pharmaceutical Group, were both included in the sixth batch of the provincial list of “specialized, refined, distinctive, and innovative” small and medium-sized enterprises.
Recently, Hebei Guangxiang Pharmaceutical Co., Ltd. and Hebei Guolong Pharmaceutical Co., Ltd., subsidiaries of Shijiazhuang Sihua Pharmaceutical Group, were both included in the sixth batch of the provincial list of “specialized, refined, distinctive, and innovative” small and medium-sized enterprises.
According to reports, “specialized, refined, distinctive, and innovative” small and medium-sized enterprises are those that possess four key strengths—professionalization, refinement, distinctiveness, and innovation—and serve as a vital driving force for economic and social development. Since 2016, Hebei Province has launched initiatives to cultivate and recognize such SMEs; in 2018, it established a database for nurturing these enterprises; and in 2019, it initiated a program to select model “specialized, refined, distinctive, and innovative” enterprises, thereby creating a tiered cultivation system that encompasses database entry and ongoing support, selective recognition, demonstration enterprise selection, and the development of “little giant” firms.
Guangxiang Pharmaceutical, a subsidiary of Shisiyao Group, is a large-scale domestic API industrialization base that leverages bulk APIs such as caffeine, metronidazole, theophylline, aminophylline, and nifedipine while also engaging in the production, R&D, and export of dozens of high-value-added specialty APIs, including arbidol, pentoxifylline, rosuvastatin calcium, and pitavastatin calcium. The company’s market influence continues to grow. Guangxiang Pharmaceutical has consistently placed R&D and innovation in API development at the core of its strategy, collaborating with leading research institutions such as Tsinghua University and Tianjin University. These partnerships have helped establish an enterprise-driven innovation system centered on industry–university–research–application linkages, technology platform development, and new product creation. By continuously advancing technological progress and innovation, the company has effectively accelerated the industrialization of new scientific and technological achievements, thereby building strong momentum for corporate transformation, upgrading, and differentiated competition.
Shisiyao Group’s Guolong Pharmaceutical boasts significant strengths in the R&D and production of specialty active pharmaceutical ingredients, with its hydroxyethyl starch product line being exclusively manufactured within the province. Guolong Pharmaceutical has established a refined and highly efficient management system and operational processes, featuring comprehensive automated production control systems, logistics systems, supply chain systems, and cost management systems. The company has introduced internationally advanced technologies and equipped itself with fully automated, information-based, and intelligent manufacturing equipment, thereby achieving refined, standardized, and scientifically driven corporate development.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091